Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint
December 07, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
November 14, 2017 06:00 ET
|
CytoDyn Inc.
PRO 140 Currently in Phase 2 Clinical Trial in Leukemia Patients Receiving Bone Marrow Transplants Preclinical Proof-of-Concept Published in Biology of Blood and Marrow Transplantation VANCOUVER,...
CytoDyn Announces Investment Community Conference Call for October 19, 2017
October 17, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA
October 13, 2017 06:00 ET
|
CytoDyn Inc.
Interim efficacy analysis of primary endpoint to be conducted in coming weeks Company to hold investment community conference call on October 19 VANCOUVER, Washington, Oct. 13, 2017 (GLOBE...
CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease
October 05, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 05, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 07, 2017 17:35 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 07, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human...
CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV
September 06, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 06, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human...
CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV
August 21, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Aug. 21, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial
August 09, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Aug. 09, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn to Present at the 7th Annual LD Micro Invitational on June 6
June 02, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 02, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...